AbbVie (ABBV) has announced that the European Commission has granted approval for ELAHERE, also known as mirvetuximab soravtansine, for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, who have undergone one to three prior systemic treatment regimens.
ELAHERE stands out as the first and only antibody-drug conjugate (ADC) targeting the folate receptor alpha to receive approval within the European Union, as well as in Iceland, Liechtenstein, Norway, and Northern Ireland.
The European Commission bestowed its approval on mirvetuximab soravtansine, marketed as ELAHERE, in November 2024. The U.S. Food and Drug Administration (FDA) had previously granted full approval in March 2024.
Furthermore, marketing authorization applications for mirvetuximab soravtansine are currently under evaluation in several additional countries.